Image For Activity Cover
Hypophosphatemic Rickets
Course Description
Hypophosphatemic rickets consists of a rare group of genetic disorders that cause renal phosphate wasting and decreased levels of 1,25 dihydroxyvitamin D. Clinically, it leads to rickets in children and bone pain, muscle weakness and osteomalacia in adults . Fibroblast growth factor- 3 (FGF23) levels are increased in both x-linked hypophosphatemic XLH and autosomal dominant hypophosphatemic rickets (ADHR) and play an important role in the pathogenesis of both conditions. Conventional treatment for both conditions consists of calcitriol and phosphate supplementation. Advances in the management of hypophosphatemic rickets include Burosumab, a monoclonal antibody against FGF-23 and the discovery that iron deficiency plays a role in the clinical manifestations of ADHR.
Target Audience
The intended audience for this activity includes a wide range of health care professionals; many may deem this presentation beneficial.
Learning Objectives
Following this activity, learners should be able to:
  • Describe the role of fibroblast growth factor – 23 (FGF23) in phosphate metabolism.
  • Review the different forms of hypophosphatemic rickets including their genetic basis and clinical phenotype.
  • Discuss the treatment of hypophosphatemic rickets with a focus on the recently approved medication, Burosumab, and the role that iron deficiency plans in the manifestation of autosomal dominant hypophosphatemic rickets.
  • Discuss acquired causes of FGF23 induced hypohyposphatemia including tumor induced osteomalacia and hypophosphatemia due to intravenous iron infusion.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Faculty and Disclosures


Lakshmi Menon, M.D.
Assistant Professor,Department of Internal Medicine, Division of Endocrinology
University of Arkansas for Medical Sciences

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported no relevant financial relationships.

The Endocrine Society staff report no relevant financial relationships.
Availability: On-Demand
Expires on Dec 31, 2024
Cost: FREE
Credit Offered:
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
Android App Download IOS App Download Powered By